Loading stock…

ResMed Inc. (RMD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ResMed Inc.

RMDMarket cap $31BPrice $220.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

ResMed makes CPAP machines and masks that keep millions of sleep apnea patients breathing at night. It dominates the sleep-tech market so thoroughly that a rival's recall handed it a massive wave of new customers overnight.

In Bastion Portfolios?

52W Return-17%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+3%3

Rev CAGR (3y)+5%4

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+16%8

EPS Growth Y+2+8%6

EPS Growth Y+3+8%6

Quality

Margins

EBIT Margin34%9

Net Income Margin27%9

Free Cash Flow Margin29%9

Debt

Net Debt/EBITDA-0.310

Efficiency

ROE24%9

ROA18%10

Earnings Stability1010

GEAR+VERY STRONG90

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)184

P/E Ratio (Forward 3y)164

P/BV4.73

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd156

Yield

Free Cash Flow Yield5.3%7

Dividend Yield1.2%4

Momentum

Short term

1 month return-3%6

3 month return+1%7

YTD return-8%4

Mid term

Price vs 52wHigh78%5

1 year return-21%2

Long term

3 year return+55%6

5 year return-9%3

Risk Shield

Price Risk

Beta0.67

Volatility29%7

Free Cash Flow

Free Cash Flow Margin29%9

Free Cash Flow Yield5.3%7

Quality

ROCE26%9

Earnings Stability1010

Net Debt/EBITDA-0.310

02Growth

Is it actually growing, and how fast?

RMDResMed

Revenue FY26$5.7B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+3%3

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+16%8

EPS growth, FY28E+8%6

EPS growth, FY29E+8%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+1%7

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-21%2

3-year return+55%6

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+1%).

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and -9.4% over five), roughly average for the market.

Returns sit at the market level over the past month (-3%) and so far this year (-8%).

WEAKNESSES

It's down 21% over the past year, now 22% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ResMed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RMDResMed

Revenue FY26$5.7B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+3%3

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+16%8

EPS growth, FY28E+8%6

EPS growth, FY29E+8%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 5%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+1%7

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-21%2

3-year return+55%6

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+1%).

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and -9.4% over five), roughly average for the market.

Returns sit at the market level over the past month (-3%) and so far this year (-8%).

WEAKNESSES

It's down 21% over the past year, now 22% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ResMed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community